• Researcher Profile

    Mark Awad, MD, PhD

     
    Mark Awad, MD, PhD
     
    Physician

    Instructor in Medicine, Harvard Medical School

    Center/Program

    Thoracic Oncology

    Office phone: 617-632-6049
    Fax: 617-632-5786

    Preferred contact method: office phone

    View Physician Profile
     
     

    Interests

    Lung cancer, Mesothelioma, Immunotherapy, Targeted therapies

    Area of Research

    Immunotherapies and Vaccine Development


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Biography

    Dr. Awad received his MD and PhD from the Johns Hopkins School of Medicine in 2008.  He completed his residency and chief residency in internal medicine at the Massachusetts General Hospital.  He received his fellowship training in medical oncology at the Dana-Farber/ Partners CancerCare program and joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2014.  His research focuses on understanding mechanisms of response and resistance to immunotherapy in lung cancer and mesothelioma, and he is involved in developing novel therapies for lung cancers with mutations in genes such as MET, RET, ALK, and ROS1.

    Recent Awards

    • Koch Institute Expansion Bridge Grant Recipient, 2016
    • Lung Cancer Developmental Research Award, Dana-Farber / Harvard Cancer Center, 2015
    • Young Investigator Award (YIA), American Society of Clinical Oncology (ASCO), 2015
    • Young Investigator Award (YIA), International Association for the Study of Lung Cancer (IASLC), 2015

    Research

    Immunotherapies and Vaccine Development

    Dr. Awad's main area of research is on cancer immunotherapy and vaccine development.  He has been working with a number of laboratories to study the genetics and immune microenvironemnt of lung tumors in order to develop better immune therapies for cancer patients.  In addition, he conducts research on cancers whose growth is driven by mutations in genes such as RET, ROS1, and ALK, and he has been working to understand how these cancers acquire resistance to targeted therapies.

View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now